Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations | Zendy

Diego KauffmannGuerrero | Zendy; Amanda Tufman | Zendy; Kathrin Kahnert | Zendy; Benjamin A. Bollmann | Zendy; Simone Reu | Zendy; Zulfiya Syunyaeva | Zendy; Christian Schneider | Zendy; Farkhad Manapov | Zendy; Rudolf M. Huber | Zendy; Heiko Golpon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations

Author(s) -

Diego KauffmannGuerrero,

Amanda Tufman,

Kathrin Kahnert,

Benjamin A. Bollmann,

Simone Reu,

Zulfiya Syunyaeva,

Christian Schneider,

Farkhad Manapov,

Rudolf M. Huber,

Heiko Golpon

Publication year - 2020

Publication title -

oncology research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.553

H-Index - 48

eISSN - 2296-5262

pISSN - 2296-5270

DOI - 10.1159/000506842

Subject(s) - stk11 , kras , immunotherapy , lung cancer , medicine , cancer research , mutation , oncology , cancer , biology , gene , genetics , colorectal cancer

Non-small cell lung cancer (NSCLC) patients with EGFR mutations do not respond well to checkpoint inhibitors. However, little is known about the activity of immunotherapy in NSCLC with other driver mutations. The increasing use of next-generation sequencing (NGS) leads to molecular findings that face the clinician with problems while choosing the best treatment. This study aims at analyzing response of NSCLC with driver mutations to immunotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research